TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04629131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 Dosage 1 (10 μg/kg)
Description: TNM002 (human monoclonal antibody against tetanus toxin), 10 μg/kg, Intramuscular injection, given once.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match TNM002 Dosage 1, given once

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 Dosage 2 (35 μg/kg)
Description: TNM002 (human monoclonal antibody against tetanus toxin), 35 μg/kg, Intramuscular injection, given once

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match TNM002 Dosage 2, given once

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 Dosage 3 (100 μg/kg)
Description: TNM002 (human monoclonal antibody against tetanus toxin), 100 μg/kg, Intramuscular injection, given once

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match TNM002 Dosage 3, given once

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 Dosage 4 (250 μg/kg)
Description: TNM002 (human monoclonal antibody against tetanus toxin), 250 μg/kg, Intramuscular injection, given once

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match TNM002 Dosage 4, given once
Study: NCT02239601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program was provided and continued throughout chemotherapy treatment
Study: NCT02902666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet
Study: NCT03181178

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Macro-micronutrient complementary food supplement
Description: This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A micronutrient powder
Description: This intervention provided a 1 g micronutrient powder with nutrition education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: This intervention provided nutrition education sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: This intervention provided nutrition education sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: This intervention provided nutrition education sessions
Study: NCT00276965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Description: Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Description: Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
Study: NCT05049304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional olive oil
Description: Eleven adolescents will consume OA-enriched functional olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: Eleven adolescents will consume olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
Study: NCT02276911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT00958958

Intervention type: OTHER
Group type: OTHER
Intervention: multifaceted strategy
Description: There are multifaceted Interventions Including~1. Distribution of educational materials: distribution of published or printed recommendations for clinical care.~2. Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used~3. Reminders~4. Practical training
Study: NCT00793871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate (SU011248)
Description: Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
Study: NCT01801943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy Group
Description: 30 min Cognitive Remediation Therapy + 60 Min Healthy Living class 3x week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Intervention (WI) Group
Description: 60 min Walking Intervention + 30 min low interface reading 3x week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination Group
Description: 30 min Cognitive Remediation Therapy + 60 min Walking Intervention 3x week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living Group
Description: 60 Min Healthy Living class + 30 min low interface reading 3x week
Study: NCT00573690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT01745263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strength Home Exercise

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Home Exercise

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Flexibility Home Exercise

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Home Exercise

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Home Exercise
Study: NCT00573690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study: NCT02276911

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT01256346

Intervention type: DEVICE
Intervention: Apparatuses
Description: Each baby will have both pulse oximetry leads (Massimo Radical 7) and electrocardiography leads (3M™ Red Dot™ Neonatal Limb Band Monitoring Electrodes, Pre-wired) applied. The time required for each modality to register a heart rate will be compared.
Study: NCT03798015

Intervention type: OTHER
Intervention: mitral valve surgery
Description: assessment of ischemic or hemorrhagic stroke subsequent to mitral valve surgery
Study: NCT03583580

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Patients are irradiated to the region of tumour bed using intensity modulated radiation therapy (IMRT)
Study: NCT03131817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S Prefrontal
Study: NCT02219880

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kava (240mg of kavalactones per day)
Description: Kava 60 milligrams per tablet = 240mg of kavalactones per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
Study: NCT00485719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally
Study: NCT02263560

Intervention type: BEHAVIORAL
Intervention: Kinematic measurements

Intervention type: BEHAVIORAL
Intervention: Kinematic measurements
Study: NCT01322243

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary manipulation
Description: Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary manipulation
Description: Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
Study: NCT00256074

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Enteral feeding formula

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Enteral feeding formula
Study: NCT01608750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazol
Description: 40mg/day, oral, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: 5 mg/day, oral, 28 days
Study: NCT04047667

Intervention type: PROCEDURE
Intervention: cone beam CT guided transbronchial cryobiopsy
Description: CBCT images are acquried and reviewed in axial, coronal and sagittal planes to most accurately assess the cryoprobe position within the lung parenchyma and relative to other thoracic structures. The minimum probe-to-pleura distance will be measured. If the position of cryoprobe is proper, TBCB will be perfomed.
Study: NCT03191383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine (GSK3003891A) formulation 1
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine (GSK3003891A) formulation 2
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine (GSK3003891A) formulation 3
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Formulation buffer S9b)
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Study: NCT03666130

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic septoplasty
Description: endoscopic septoplasty is the use of nasal endoscopy in the septoplasty surgery for treatment of deviated nasal septum . we aim to compare the outcome of using this method versus conventional septoplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic septoplasty
Description: endoscopic septoplasty is the use of nasal endoscopy in the septoplasty surgery for treatment of deviated nasal septum . we aim to compare the outcome of using this method versus conventional septoplasty
Study: NCT00980863

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention to increase physical activity

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: lifestyle intervention to increase physical activity
Study: NCT01205776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
Study: NCT01808313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ambrisentan
Description: Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
Study: NCT03072901

Intervention type: DEVICE
Intervention: EndoBarrier Gastrointestinal Liner
Description: The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
Study: NCT03947645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipsilesional stimulation
Description: Device: ipsilesional transcranial stimulation, neuromuscular Stimulation over target muscle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralesional stimulation
Description: Device: contralesional transcranial stimulation, neuromuscular stimulation over target muscle
Study: NCT03710434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 50 mg nano-suspension (reference)
Description: Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 solid oral formulation - fasted
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 solid oral formulation - fasted
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 solid oral formulation - fasted
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 solid oral formulation - fed
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole and AZD4635 50 mg solid oral formulation
Description: Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 solid oral formulation variant 1 - fasted
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 solid oral formulation variant 2 - fasted
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] AZD4635 IV microtracer - fasted
Description: Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
Study: NCT00816517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of botulinum toxin type A.
Description: 35 to 100 units injected around a skin lesion (plaque) one time.
Study: NCT03943368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceevra Reveal
Description: 3D Digital models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source MR image.
Study: NCT01388387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tacrolimus pharmacokinetics
Description: tacrolimus pharmacokinetics over 12 hours
Study: NCT01631032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qi-tonifying Chinese herbal products
Description: Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
Study: NCT04790409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab and anlotinib
Description: This study was a one-arm, open-label, phase II study of PD-1 monoclonal antibody combined with ilotinib in the treatment of advanced EGFR rare-mutant non-small cell lung cancer (NSCLC). 21 patients enrolled in the study who underwent platinum-containing systemic chemotherapy and EGFR-TKI failure were enrolled in the study.
Study: NCT01752322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated plaster

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plaster
Study: NCT01261416

Intervention type: DRUG
Intervention: levetiracetam
Description: Patients will receive levetiracetam as needed for clinical and/or electrographic seizures. Need for levetiracetam will be determined by the clinical team and will NOT determined by the study protocol.
Study: NCT02923115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Subcutaneous injection 1 mg/kg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous injection 1 mg/kg twice daily
Study: NCT06416761

Intervention type: GENETIC
Intervention: genetic polymorphisms
Study: NCT03801759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: Oral Adefovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral Digoxin
Study: NCT02424656

Intervention type: PROCEDURE
Intervention: MRI
Description: EEG-functional MRI, structural MRI, diffusion MRI

Intervention type: PROCEDURE
Intervention: MRI
Description: EEG-functional MRI, structural MRI, diffusion MRI

Intervention type: PROCEDURE
Intervention: TMS-EEG
Description: Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation

Intervention type: PROCEDURE
Intervention: TMS-EEG
Description: Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation

Intervention type: PROCEDURE
Intervention: FDG-PET

Intervention type: PROCEDURE
Intervention: FDG-PET

Intervention type: OTHER
Intervention: Clinical scales
Description: Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
Study: NCT02602561

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01804530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX7486 TsOH
Description: PLX7486 TsOH capsules, 50mg
Study: NCT03638752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive education group
Description: The details of Comprehensive education are as follows:~1. introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~2. instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~3. provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~4. inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~5. inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~6. inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting.
Study: NCT03999229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNO
Description: S-nitrosylating agent (SNO) Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SNO
Description: S-nitrosylating agent (SNO) Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline transfusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell
Description: Blood transfusion (RBCs)
Study: NCT04254731

Intervention type: DRUG
Group type: OTHER
Intervention: Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)
Study: NCT01205776

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: Those patients receiving CABG
Study: NCT02863094

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Study: NCT02263430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation